Nivetha Ramesh Babu

Nivetha Ramesh Babu

Auto-generated profile, based on publicly available information

Nivetha Ramesh Babu

Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Cancer Discovery
Verified
Journal Article
Closed access
NNNicholas J. Neill
Nicholas J. Neill
SSShankha Satpathy
Shankha Satpathy
KKKarsten Krug
Karsten Krug
JMJitendra K. Meena
Jitendra K. Meena
NBNivetha Ramesh Babu
Nivetha Ramesh Babu
TWThomas F. Westbrook
Thomas F. Westbrook
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with few effective targeted therapies. Taxanes and other microtubule-targeting agents (MTA) are first-line chemotherapies for TNBC; however, the molecular mechanisms that underlie TNBC taxane sensitivity are largely unknown, preventing selection of taxane-responsive patients and development of more selective therapeutic strategies. In this study, we identified tumor-selective vulnerabilities in TNBC harboring inactivation of the tumor suppressor PTPN12 by integrating proteogenomic characterization and synthetic lethality screening. We discovered that PTPN12 inactivation drives mitotic defects through aberrant hyperactivation of the ubiquitin ligase complex APCFZR1, a critical regulator of the cell cycle. Consistent with the mitotic stress caused by PTPN12 inactivation in TNBC cell lines, tumors harboring loss of PTPN12 exhibit heightened sensitivity to taxane chemotherapy. Collectively, these data suggests that PTPN12 inactivation may drive chromosomal instability and favorable MTA response in TNBC—two prominent features of the disease with unclear mechanistic etiology. Significance: Many TNBCs respond to MTAs, but the underlying cause(s) of this sensitivity remain poorly understood. Herein, we discover that the tumor suppressor PTPN12 regulates mitotic fidelity and MTA sensitivity in a large subset of patients with TNBC, which has significant implications for the use of MTAs in breast cancer.

3 November 2025
Verified
Other
Open access
PDF file
NNNicholas J. Neill
Nicholas J. Neill
SSShankha Satpathy
Shankha Satpathy
KKKarsten Krug
Karsten Krug
JMJitendra K. Meena
Jitendra K. Meena
NBNivetha Ramesh Babu
Nivetha Ramesh Babu
TWThomas F. Westbrook
Thomas F. Westbrook
Figure S3: PTPN12-deficient cells are vulnerable to perturbation of mitotic regulators (related to Figure 3).

3 November 2025
Verified
Other
Open access
NNNicholas J. Neill
Nicholas J. Neill
SSShankha Satpathy
Shankha Satpathy
KKKarsten Krug
Karsten Krug
JMJitendra K. Meena
Jitendra K. Meena
NBNivetha Ramesh Babu
Nivetha Ramesh Babu
TWThomas F. Westbrook
Thomas F. Westbrook
Table S2: Proteogenomic fold-change data (PTPN12 normal vs deficient) (related to Figure 2).

3 November 2025
Verified
Other
Open access
PDF file
NNNicholas J. Neill
Nicholas J. Neill
SSShankha Satpathy
Shankha Satpathy
KKKarsten Krug
Karsten Krug
JMJitendra K. Meena
Jitendra K. Meena
NBNivetha Ramesh Babu
Nivetha Ramesh Babu
TWThomas F. Westbrook
Thomas F. Westbrook
Figure S5: PTPN12-deficient cells exhibit mitotic defects dependent on APCFZR1 hyperactivation (related to Figure 5).

3 November 2025
Verified
Other
Open access
PDF file
NNNicholas J. Neill
Nicholas J. Neill
SSShankha Satpathy
Shankha Satpathy
KKKarsten Krug
Karsten Krug
JMJitendra K. Meena
Jitendra K. Meena
NBNivetha Ramesh Babu
Nivetha Ramesh Babu
TWThomas F. Westbrook
Thomas F. Westbrook
Figure S1: Integration of proteogenomics and functional genetics to reveal novel vulnerabilities in TNBC (related to Figure 1).

3 November 2025
Verified
Other
Open access
NNNicholas J. Neill
Nicholas J. Neill
SSShankha Satpathy
Shankha Satpathy
KKKarsten Krug
Karsten Krug
JMJitendra K. Meena
Jitendra K. Meena
NBNivetha Ramesh Babu
Nivetha Ramesh Babu
TWThomas F. Westbrook
Thomas F. Westbrook
Table S1: PDX proteogenomic data (related to Figure 2).